Health
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
NEW YORK, February 24, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/497a29db16c445c2363959533726e412"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/duG39Ft29c2RVLZc1WCoeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/497a29db16c445c2363959533726e412","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancer","length":132,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Pivotal results from the Phase 3 portion with mFOLFOX6 of the BREAKWATER trial demonstrated a clinically meaningful and statistically significant 51% risk reduction in death and a 47% risk reduction in disease progression or death compared to chemotherapy treatment with or without bevacizumab","length":293,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expanded indication enables flexibility to use BRAFTOVI in combination with cetuximab and different fluorouracil-based chemotherapy regimens","length":140,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":565,"olType":false},{"type":"text","content":"NEW YORK, February 24, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).","length":453,"tagName":"p"},{"type":"text","content":"BRAFTOVI in combination with cetuximab and mFOLFOX6 was granted accelerated approval by the FDA in December 2024 based on objective response rate (ORR) results, one of the BREAKWATER trial’s dual primary endpoints. The conversion from accelerated approval to full approval is based on significant benefit in outcomes for both progression-free survival (PFS), the trial’s other primary endpoint, and overall survival (OS), a key secondary endpoint, from the Phase 3...